Studies involving disease:Spinal cord injury
| Study ID | Study Title | Species | Institute |
|---|---|---|---|
| ST000792 | Large Untargeted Profiling of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000793 | Targeted FFA Composition of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000794 | Targeted NEFA Panel of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000795 | Targeted Cholesterol Profiling of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000796 | Targeted Sphingolipids Panel of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000797 | Targeted Galactosyl Sphingolipids Concentrations of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000798 | Targeted Sphinomyelin Panel of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000799 | Targeted TCA Panel of Myelin to Enhance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000848 | Targeting Myelin NEFA of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000849 | Targeting Myelin FFA Compostion of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000850 | Targeting Myelin Cholesterol of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000851 | Targeting Myelin Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000852 | Targeting Myelin Galactosyl Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000853 | Targeting Myelin Sphinomyelin concentrations of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Mouse | Mayo Clinic |
| ST000854 | Targeted FFA Composition in Kallikrein 6 Mice after SCI | Mouse | Mayo Clinic |
| ST000856 | Targeted NEFA in Kallikrein 6 Mice after SCI | Mouse | Mayo Clinic |
| ST000857 | Targeted Cholesterol Profiling of Myelin to Enhance Recovery of Function after SCI. Second Set of Samples | Mouse | Mayo Clinic |
| ST000858 | Targeted Sphingolipids in Kallikrein 6 Mice after SCI | Mouse | Mayo Clinic |
| ST000859 | Targeted Galactosyl Sphingolipid Concentration in Kallikrein 6 Mice after SCI | Mouse | Mayo Clinic |
| ST000860 | Targeted Sphingomyelin Concentrations in Kallikrein 6 Mice after SCI | Mouse | Mayo Clinic |
| ST000861 | Targeting Myelin NEFA in PAR1 and PAR2 Mice after SCI | Mouse | Mayo Clinic |
| ST000862 | Targeting Myelin FFA Compostion in PAR1 and PAR2 Mice after SCI | Mouse | Mayo Clinic |
| ST000863 | Targeting Myelin Cholesterol in PAR1 and PAR2 Mice after SCI | Mouse | Mayo Clinic |
| ST000864 | Targeting Myelin Ceramides in PAR1 and PAR2 Mice after SCI | Mouse | Mayo Clinic |
| ST000866 | Large Untargeted Profiling in PAR1 and PAR2 Mice after SCI | Mouse | Mayo Clinic |
| ST000869 | Large Untargeted Profiling in Kallikrein 6 Mice after SCI | Mouse | Mayo Clinic |
| ST004170 | Untargeted Metabolomics for Assessing Neural Stem Cell Therapy in Spinal Cord Injury | Rat | Nanjing University |